Boston Scientific/Penumbra: EC Gears Up for Deal Probe with Inquiries to Industry Players

The European Commission, in preparation of launching a formal review of Boston Scientific’s (BSX) proposed acquisition of Penumbra (PEN), has begun setting up interviews and requesting information from industry players about the $14.5 billion deal’s impact, sources familiar with the matter said

Published on Oct 22, 2026

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2026 The Capitol Forum. All Rights Reserved.